Imugene Ltd
IMU
Company Profile
Business description
Imugene Ltd specializes in a clinical-stage immuno-oncology company. Its products include HER-Vaxx, PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment is the Research and Development of oncolytic immunotherapies.
Contact
4-6 Bligh Street
Suite 12.01, Level 12
SydneyNSW2000
AUSSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
5
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,511.90 | 46.90 | 0.55% |
CAC 40 | 7,393.76 | 13.02 | 0.18% |
DAX 40 | 20,024.66 | 115.52 | 0.58% |
Dow JONES (US) | 42,392.27 | 151.95 | -0.36% |
FTSE 100 | 8,260.09 | 87.07 | 1.07% |
HKSE | 19,704.16 | 80.84 | 0.41% |
NASDAQ | 19,280.79 | 30.00 | -0.16% |
Nikkei 225 | 39,894.54 | 386.62 | -0.96% |
NZX 50 Index | 13,067.83 | 42.91 | -0.33% |
S&P 500 | 5,868.55 | 13.08 | -0.22% |
S&P/ASX 200 | 8,250.50 | 49.30 | 0.60% |
SSE Composite Index | 3,211.43 | 51.13 | -1.57% |